{{expand language|en}}
{{noteTA
|T = zh-cn:莫德纳2019冠状病毒病疫苗; zh-hk:莫德納2019冠狀病毒病疫苗; zh-mo:莫德納2019冠狀病毒病疫苗; zh-tw:莫德納嚴重特殊傳染性肺炎疫苗; zh-sg:莫德纳2019冠状病毒疾病疫苗; zh-my:莫德纳2019冠状病毒病疫苗;
|G1=ME
|1=zh-tw:資訊;zh-hk:資訊;zh-hans:信息;
}}
{{medical}}
{{Infobox drug
| Verifiedfields    =
| verifiedrevid     =
| drug_name         =
| INN               =
| image             = Moderna COVID-19 vaccine.jpg
| alt               =
| width             = 250
| caption           = 莫德納疫苗的包裝外觀

<!-- Vaccine data -->
| target            = [[SARS-CoV-2|SARS-CoV-2]]
| vaccine_type      = [[mRNA|mRNA]]

<!-- Clinical data -->
| pronounce         = {{IPAc-en|m|ə|ˈ|d|ɜːr|n|ə}} {{respell|mə|DUR|nə}}<ref>{{cite AV media |people=Moderna|date=October 23, 2019|title=mRNA-3704 and Methylmalonic Acidemia|medium=Video|url=https://www.youtube.com/watch?v=eb8OHaF8wio|access-date=January 19, 2021|publisher=YouTube}}</ref>
| tradename         = Spikevax<ref name="COVID-19 Vaccine Moderna EPAR"/>
| Drugs.com         = {{drugs.com|mtm|moderna-covid-19-vaccine}}
| MedlinePlus       = a621002
| licence_EU        =
| DailyMedID        = Moderna_COVID-19_Vaccine
| licence_US        =
| pregnancy_AU      =
| pregnancy_AU_comment =
| pregnancy_category =
| routes_of_administration = [[肌肉注射|肌肉注射]]
| ATC_prefix        = None <!-- scheduled to be J07BX03 in 2022 -->
| ATC_suffix        =
| ATC_supplemental  =

<!-- Legal status -->
| legal_AU          = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment  =
| legal_BR          = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment  =
| legal_CA          = Schedule D; Authorized by interim order
| legal_CA_comment  = <ref name="CA Moderna decision">{{cite web | title=Regulatory Decision Summary – Moderna COVID-19 Vaccine | website=[[加拿大衛生部|Health Canada]] | date=23 December 2020 | url=https://covid-vaccine.canada.ca/info/regulatory-decision-summary-detailTwo.html?linkID=RDS00736 | access-date=23 December 2020}}</ref><ref name="CA Moderna product description">{{cite web | title=Moderna COVID-19 Vaccine (mRNA-1273 SARS-CoV-2) | website=COVID-19 vaccines and treatments portal | date=23 December 2020 | url=https://covid-vaccine.canada.ca/moderna-covid-19-vaccine/product-details | access-date=23 December 2020}}</ref>
| legal_DE          = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment  =
| legal_NZ          = <!-- Class A, B, C -->
| legal_NZ_comment  =
| legal_UK          = Conditional and temporary authorization to supply
| legal_UK_comment  = <ref>{{cite web | title=Information for Healthcare Professionals on COVID-19 Vaccine Moderna | website={{tsl|en|Medicines and Healthcare products Regulatory Agency||Medicines and Healthcare products Regulatory Agency}} (MHRA) | date=8 January 2021 | url=https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/information-for-healthcare-professionals-on-covid-19-vaccine-moderna | access-date=8 January 2021}}</ref><ref>{{cite web | title=Conditions of Authorisation for COVID-19 Vaccine Moderna | website={{tsl|en|Medicines and Healthcare products Regulatory Agency||Medicines and Healthcare products Regulatory Agency}} (MHRA) | date=8 January 2021 | url=https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/conditions-of-authorisation-for-covid-19-vaccine-moderna | access-date=9 January 2021}}</ref>
| legal_US          = Standing Order; Unapproved
| legal_US_comment  = ({{tsl|en|Emergency Use Authorization||Emergency Use Authorization}})<ref name="FDA PR 20201218">{{cite press release | title=FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine | website=U.S. [[美国食品药品监督管理局|美国食品药品监督管理局]]| url=https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid | access-date=18 December 2020}}</ref><ref name="Moderna COVID-19 Vaccine FDA label">{{cite web | title=Moderna COVID-19 Vaccine – cx-024414 injection, suspension | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0651c7a-2fe2-459d-a766-0d59e919f058 | access-date=20 December 2020}}</ref><ref name="Moderna COVID-19 Vaccine FDA EUA">{{cite report | url=https://www.fda.gov/media/144636/download | format=PDF | title=Moderna COVID-19 Vaccine Emergency Use Authorization | website=U.S. [[美国食品药品监督管理局|Food and Drug Administration]] (FDA) | date=18 December 2020 | access-date=20 December 2020}} {{PD-notice}}</ref><ref>{{cite web | url=https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/standing-orders.pdf | title=Moderna COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older | publisher=[[美国疾病控制与预防中心|Centers for Disease Control and Prevention]] (CDC)}}</ref>
| legal_EU          = Conditional marketing authorization granted
| legal_EU_comment  = <ref name="COVID-19 Vaccine Moderna EPAR">{{cite web | title=COVID-19 Vaccine Moderna EPAR | website=[[欧洲药品管理局|European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna | access-date=20 January 2021}}</ref><ref name="EU approval">{{cite press release|title=European Commission authorises second safe and effective vaccine against COVID-19|url=https://ec.europa.eu/commission/presscorner/detail/en/ip_21_3|access-date=6 January 2021|website=European Commission }}</ref>
| legal_UN          = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment  =
| legal_status      = <!-- For countries not listed above -->

<!-- Identifiers -->
| CAS_number_Ref    =
| CAS_number        =
| CAS_supplemental  =
| PubChem           =
| IUPHAR_ligand     =
| DrugBank_Ref      =
| DrugBank          = DB15654
| ChemSpiderID_Ref  =
| ChemSpiderID      =
| UNII_Ref          =
| UNII              = EPK39PL4R4
| KEGG_Ref          =
| KEGG              =
| ChEBI_Ref         =
| ChEBI             =
| ChEMBL_Ref        =
| ChEMBL            =
| NIAID_ChemDB      =
| PDB_ligand        =
| synonyms          = mRNA-1273<br/>CX-024414<br/>COVID-19 mRNA Vaccine Moderna<br/>莫德納疫苗

<!-- Chemical and physical data -->
| IUPAC_name        =
| chemical_formula_ref =
| chemical_formula  =
| C= | H= | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I=
| K= | Li= | Mg= | Mn= | N= | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge=
| molecular_weight  =
| molecular_weight_comment =
| SMILES            =
| StdInChI          =
| StdInChI_comment  =
| StdInChIKey       =
| density           =
| density_notes     =
| melting_point     =
| melting_high      =
| melting_notes     =
| boiling_point     =
| boiling_notes     =
| solubility        =
| specific_rotation =
}}
[[File:201228-F-VS137-1009.jpg|thumb]]
'''莫德纳2019冠状病毒病疫苗'''（{{lang-en|Moderna COVID‑19 vaccine}}，簡稱：'''莫德納疫苗'''，代號：'''mRNA-1273'''，[[商品名|商品名]]：'''{{lang|en|Spikevax}}'''，[[國際非專利藥品名稱|國際非專利藥品名稱]]：elasomeran<ref name="INN">{{cite press release | title=TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran | website=Therapeutic Goods Administration (TGA) | date=24 June 2021 | url=https://www.tga.gov.au/media-release/tga-grants-provisional-determination-moderna-covid-19-vaccine-elasomeran | access-date=29 June 2021}}</ref>），是[[美國國家過敏和傳染病研究所|美國國家過敏和傳染病研究所]]、{{tsl|en|Biomedical Advanced Research and Development Authority|生物醫學高級研究與開發管理局}}和[[莫德纳|莫德納公司]]合作開發的[[2019冠状病毒病疫苗|2019冠状病毒病疫苗]]，為一種[[信使核糖核酸|信使核糖核酸]]（mRNA）疫苗，在2020年12月發表的第三期臨床試驗報告顯示該疫苗的有效率達94%<ref name="bbc-2020-12-19">{{cite news |title=美國批准第二種疫苗莫德納　彭斯夫婦接種疫苗 |url=https://www.bbc.com/zhongwen/trad/world-55375185 |accessdate=2021-04-22 |work=BBC |date=2020-12-19}}</ref>。該疫苗需要以[[肌肉注射|肌肉注射]]方式接種兩次，每次的劑量為0.5毫升，兩次之間相隔4週<ref name="IDSA">{{cite web | title = Moderna COVID-19 Vaccine | work = Dosing & Administration | publisher = {{tsl|en|Infectious Diseases Society of America||Infectious Diseases Society of America}} | date = 4 January 2021 | url = https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/moderna-covid-19-vaccine/ | access-date = 5 January 2021 }}</ref>。

2020年12月18日，mRNA-1273獲得[[美國食品藥品管理局|美國食品藥品管理局]]核發[[緊急使用授權|緊急使用授權]]<ref name="FDA PR 20201218" /><ref name="nih-eua">{{cite news |title=Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Moderna COVID-19 Vaccine |url=https://www.nih.gov/news-events/news-releases/statement-nih-barda-fda-emergency-use-authorization-moderna-covid-19-vaccine |access-date=19 December 2020 |agency=US National Institutes of Health |date=18 December 2020}}</ref><ref name="CDC ACIP Moderna COVID-19 Vaccine">{{cite journal|vauthors=Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Outcalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K|display-authors=6|date=January 2021|title=The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine – United States, December 2020|journal=MMWR Morbidity and Mortality Weekly Report|volume=69|issue=5152|pages=1653–56|doi=10.15585/mmwr.mm695152e1|pmid=33382675| url=https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm695152e1-H.pdf}}</ref><ref name="lovelace">{{cite news |first=Berkeley | last=Lovelace Jr | |date=19 December 2020|title=FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution|url=https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html|access-date=19 December 2020|work=CNBC}}</ref>，其後在2020年12月23日在[[加拿大|加拿大]]<ref name="CA Moderna decision" /><ref name="CA Moderna product description" />、2021年1月6日在[[歐盟|歐盟]]<ref name="COVID-19 Vaccine Moderna EPAR" /><ref name="EU UR info">{{cite web | title=COVID-19 Vaccine Moderna | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1507.htm | access-date=14 January 2021}}</ref><ref name="EU approval" />、2021年1月8日在[[英國|英國]]<ref>{{cite web | title=Moderna vaccine becomes third COVID-19 vaccine approved by UK regulator | website=U.K. Government | date=8 January 2021 | url=https://www.gov.uk/government/news/moderna-vaccine-becomes-third-covid-19-vaccine-approved-by-uk-regulator | access-date=8 January 2021}}</ref>，獲發出緊急使用授權。[[世衛組織|世衛組織]]於2021年4月30日將該疫苗列入緊急使用清單<ref name="who-2021-04-30">{{cite news |title=WHO lists Moderna vaccine for emergency use |url=https://www.who.int/news/item/30-04-2021-who-lists-moderna-vaccine-for-emergency-use |accessdate=2021-05-06 |work=World Health Organization |date=2021-04-30}}</ref>。

== 開發及試驗==
2020年1月，莫德納宣佈將會開發一款能夠誘發針對[[SARS-CoV-2|SARS-CoV-2]]的免疫力的[[RNA疫苗|RNA疫苗]]mRNA-1273<ref>{{Cite news|url=https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8|title=With Wuhan virus genetic code in hand, scientists begin work on a vaccine|last1=Steenhuysen|first1=Julie|last2=Kelland|first2=Kate|date=2020-01-24|work=Reuters|access-date=2020-01-26|language=en|archive-date=2020-01-25|archive-url=https://web.archive.org/web/20200125203723/https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8}}</ref><ref name="carey">{{cite web |author1=Karen Carey |title=Increasing number of biopharma drugs target COVID-19 as virus spreads |url=https://www.bioworld.com/articles/433331-increasing-number-of-biopharma-drugs-target-covid-19-as-virus-spreads |publisher=BioWorld |accessdate=1 March 2020 |date=February 26, 2020 |archive-date=27 February 2020 |archive-url=https://web.archive.org/web/20200227150718/https://www.bioworld.com/articles/433331-increasing-number-of-biopharma-drugs-target-covid-19-as-virus-spreads}}</ref><ref name="everett">{{cite web |author1=Gwen Everett |title=These 5 drug developers have jumped this week on hopes they can provide a coronavirus treatment |url=https://markets.businessinsider.com/news/stocks/drug-stocks-gain-companies-coronavirus-vaccine-potential-wall-street-buys-2020-2-1028947495 |publisher=Markets Insider |accessdate=1 March 2020 |date=February 27, 2020 |archive-date=2020-11-16 |archive-url=https://web.archive.org/web/20201116154220/https://markets.businessinsider.com/news/stocks/drug-stocks-gain-companies-coronavirus-vaccine-potential-wall-street-buys-2020-2-1028947495}}</ref>。mRNA-1273能夠通過編碼天然存在於SARS-CoV-2表面的預融合穩定刺突（S）蛋白來誘導對SARS-CoV-2的免疫力<ref>{{cite web | url=https://www.bloomberg.com/news/articles/2020-05-18/mit-professor-s-moderna-stake-on-the-brink-of-topping-1-billion | title=MIT Professor's Moderna Stake on the Brink of Topping $1 Billion | first1=Devon | last1=Pendleton | first2=Tom | last2=Maloney | website=[[Bloomberg_News|Bloomberg News]] | date=18 May 2020 | accessdate=18 May 2020 | quote=CEO Bancel, other Moderna executives have been selling shares }}</ref>。

莫德纳聲稱mRNA-1273疫苗在標準[[醫療冷櫃|醫療冷櫃]]2--8°C（36--46°F）環境中，可儲藏至多30天；在零下20°C（−4°F）的環境中可儲藏至多4個月。<ref name=cnbc11-16/>

=== 臨床I至II期試驗 ===
2020年3月，mRNA-1273的[[臨床I期|臨床I期]]人體試驗開始，[[美國國家過敏和傳染病研究所|美國國家過敏和傳染病研究所]]為合作伙伴<ref>{{cite web |title=NIH clinical trial of investigational vaccine for COVID-19 begins |url=https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins |website=National Institutes of Health (NIH) |accessdate=18 March 2020 |language=EN |date=16 March 2020 |archive-date=19 March 2020 |archive-url=https://web.archive.org/web/20200319120523/https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins}}</ref>。莫德納與[[瑞士|瑞士]]製藥商[[龍沙集團|龍沙集團]]簽訂合作協議，由後者提供每年3億劑的產能<ref>{{Cite web|url=https://www.swissinfo.ch/eng/sci-tech/swiss-factory-rushes-to-prepare-for-moderna-covid-19-vaccine/46081656|title=Swiss factory rushes to prepare for Moderna Covid-19 vaccine|website=SWI swissinfo.ch|access-date=2020-10-07|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116154307/https://www.swissinfo.ch/eng/sci-tech/swiss-factory-rushes-to-prepare-for-moderna-covid-19-vaccine/46081656}}</ref>。

2020年5月25日，莫德納開始[[臨床IIa期試驗|臨床IIa期試驗]]，共招募600位成年志願者測試疫苗的安全性和疫苗誘發的[[抗體|抗體]]水平差異<ref name="mod-04405076">{{ClinicalTrialsGov|NCT04405076|Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older}}</ref>。

2020年7月14日，莫德納的科學家發表了mRNA-1273的I期劑量遞增臨床試驗的初步結果。結果顯示，依劑量不同，最早於注射後第15天，針對S1和S2的中和抗體已被誘發。在所有劑量組中均觀察到輕度至中度的[[不良反應|不良反應]]，如[[發燒|發燒]]，乏力，頭痛，[[肌肉酸痛|肌肉酸痛]]和注射部位疼痛，在大劑量組中更為常見<ref name="jackson">{{cite journal |author1=Lisa A Jackson |author2=mRNA-1273 Study Group |title=An mRNA Vaccine against SARS-CoV-2 — Preliminary Report |journal=The New England Journal of Medicine |date=July 2020 |volume=383 |issue=20 |pages=1920–1931 |doi=10.1056/NEJMoa2022483 |pmid=32663912 |pmc=7377258}}</ref><ref>{{cite web|url=https://www.cnbc.com/2020/07/14/stock-market-futures-open-to-close-news.html|title=Dow futures jump more than 200 points after Moderna says its vaccine produces antibodies to coronavirus|author=Yun Li|publisher=[[CNBC|CNBC]]|date=July 14, 2020|accessdate=July 15, 2020|archive-date=November 16, 2020|archive-url=https://web.archive.org/web/20201116154335/https://www.cnbc.com/2020/07/14/stock-market-futures-open-to-close-news.html}}</ref><ref name="jackson-app">{{cite journal |author1=Lisa A Jackson |author2=mRNA-1273 Study Group |title=Supplementary appendix for 'An mRNA Vaccine against SARS-CoV-2 — Preliminary Report' |journal=The New England Journal of Medicine |date=July 2020 |doi=10.1056/NEJMoa2022483 |pmid=32663912 |pmc=7377258 |url=https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl_file/nejmoa2022483_appendix.pdf |access-date=2020-07-15 |archive-date=2020-07-14 |archive-url=https://web.archive.org/web/20200714224420/https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl_file/nejmoa2022483_appendix.pdf}}</ref>。低劑量的疫苗被認為是安全且有效的，可以進行相距29天的兩次100μg劑量的[[臨床III期試驗|臨床III期試驗]]<ref name="jackson" />。 

=== 臨床III期試驗 ===
莫德納和美國國家過敏和傳染病研究所於2020年7月27日在美國展開[[臨床III期試驗|臨床III期試驗]]，計劃招募3萬名志願者並將他們隨機分為兩組——一組注射兩劑100μg的mRNA-1273疫苗，另一組則注射[[安慰劑|安慰劑]]（0.9%的[[生理鹽水|生理鹽水]]）。<ref name="palca">{{cite news |last1=Palca |first1=Joe |title=COVID-19 vaccine candidate heads to widespread testing in U.S. |url=https://www.npr.org/sections/coronavirus-live-updates/2020/07/27/895672859/us-vaccine-candidate-heads-to-widespread-testing-in-people |accessdate=27 July 2020 |work=NPR |date=27 July 2020 |archive-date=11 October 2020 |archive-url=https://web.archive.org/web/20201011084836/https://www.npr.org/sections/coronavirus-live-updates/2020/07/27/895672859/us-vaccine-candidate-heads-to-widespread-testing-in-people/}}</ref>

2020年11月16日，莫德納公佈其臨床III期試驗的初步數據，顯示mRNA-1273對預防感染[[2019冠狀病毒病|2019冠狀病毒病]]的效力達到94%<ref name="cnbc11-16">{{cite news |author1=Berkeley Lovelace, Jr. |author2=Noah Higgins-Dunn|title= Moderna says preliminary trial data shows its coronavirus vaccine is more than 94% effective, shares soar|url=https://www.cnbc.com/2020/11/16/moderna-says-its-coronavirus-vaccine-is-more-than-94percent-effective.html |accessdate=17 November 2020 |work=CNBC |date=16 November 2020}}</ref><ref name="NYT-20201120">{{cite news |last=Zimmer |first=Carl |authorlink=Carl Zimmer |title=2 Companies Say Their Vaccines Are 95% Effective. What Does That Mean? You might assume that 95 out of every 100 people vaccinated will be protected from Covid-19. But that's not how the math works. |url=https://www.nytimes.com/2020/11/20/health/covid-vaccine-95-effective.html |date=20 November 2020 |work=The New York Times |accessdate=21 November 2020 }}</ref>，[[副作用|副作用]]則包括類似流感的症狀，如注射部位疼痛、乏力、[[肌肉痠痛|肌肉痠痛]]、頭痛等。<ref name=cnbc11-16/>這並非臨床試驗的最終結果，因為莫德納的臨床試驗計劃至2022年末方有正式結論。<ref name="NCT04470427">{{cite web |title=A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04470427?term=moderna&cond=covid-19&draw=2&rank=1 |publisher=Clinicaltrials.gov, US National Library of Medicine |accessdate=17 November 2020 |date=28 October 2020}}</ref>

2020年12月30日，莫德納將mRNA-1273的第三期臨床試驗數據、安全性及有效率的論文刊登於《[[新英格蘭醫學期刊|新英格蘭醫學期刊]]》發表<ref name="nejm-2020-12-30">{{cite journal |author1=Lindsey R. Baden, M.D., Hana M. El Sahly, M.D., Brandon Essink, M.D., Karen Kotloff, M.D., Sharon Frey, M.D., Rick Novak, M.D., David Diemert, M.D., Stephen A. Spector, M.D., Nadine Rouphael, M.D., C. Buddy Creech, M.D., John McGettigan, M.D., Shishir Khetan, M.D., Nathan Segall, M.D., Joel Solis, M.D., Adam Brosz, M.D., Carlos Fierro, M.D., Howard Schwartz, M.D., Kathleen Neuzil, M.D., Lawrence Corey, M.D., Peter Gilbert, Ph.D., Holly Janes, Ph.D., Dean Follmann, Ph.D., Mary Marovich, M.D., John Mascola, M.D., Laura Polakowski, M.D., Julie Ledgerwood, D.O., Barney S. Graham, M.D., Hamilton Bennett, M.S., Rolando Pajon, Ph.D., Conor Knightly, M.P.H., Brett Leav, M.D., Weiping Deng, Ph.D., Honghong Zhou, Ph.D., Shu Han, Ph.D., Melanie Ivarsson, Ph.D., Jacqueline Miller, M.D., Tal Zaks, M.D. |title=Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine |url=https://www.nejm.org/doi/full/10.1056/nejmoa2035389 |accessdate=2021-04-22 |journal=The New England Journal of Medicine |date=2020-12-30|archive-url=https://web.archive.org/web/20201230231259/https://www.nejm.org/doi/full/10.1056/nejmoa2035389 |archive-date=2020-12-30 |dead-url=no }}</ref>。

=== 後續調查及統計 ===
莫德納在2021年4月13日表示，追踪超過3萬名已經接種兩劑疫苗的第三期臨床試驗參與者6個月後，至4月9日有900宗確診個案，顯示疫苗在6個月後的整體有效率仍達到90%，而預防重症的效力則為95%，莫德納同時稱已供應全球約1億3200萬劑疫苗，包括美國的1億1700萬劑，預期供應美國3億劑疫苗的目標可於7月底前達標<ref name="cna-2021-04-14">{{cite news |title=莫德納疫苗施打6個月 各類型病毒效力仍達9成 |url=https://www.cna.com.tw/news/aopl/202104140102.aspx |accessdate=2021-05-03 |work=中央通訊社 |date=2021-04-14}}</ref>。

== 授權使用 ==
{{seealso|2019冠状病毒病疫苗授权列表}}
2020年11月30日，莫德纳公司宣布将于当日向[[美国食品药品监督管理局|美国食品药品监督管理局]]申请该疫苗的[[緊急使用授權|緊急使用授權]]，并向[[欧洲药品管理局|欧盟药品管理局]]等全球多家监管机构提交了滚动申请。莫德纳表示到2020年底，该公司预计将在美国运送约2000万剂疫苗，2021年有望在全球生产5至10亿剂<ref>{{Cite web|title=Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization|url=https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study/|accessdate=2020-12-02|author=|date=2020-11-30|format=|publisher=investors.modernatx.com|language=en|archiveurl=https://web.archive.org/web/20201202031827/https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study/|archivedate=2020-12-02}}</ref>。莫德納在2020年11月向德國媒體《[[世界報_(德國)|週日世界報]]》透露每劑疫苗的售價約25至37美元，視乎訂單的數量而定<ref>{{Cite web|title=Moderna to charge $25-$37 for COVID-19 vaccine, says CEO|url=https://indianexpress.com/article/coronavirus/moderna-covid-19-vaccine-cost-7060816/|access-date=2021-05-18|date=2020-11-22|work=The Indian Express|language=en}}</ref><ref>{{Cite news|title=Moderna to charge $25-$37 for COVID-19 vaccine: CEO tells paper|url=https://www.reuters.com/article/us-health-coronavirus-moderna-eu-idUSKBN2810W4|newspaper=Reuters|date=2020-11-22|accessdate=2021-05-18|language=en|first=Reuters|last=Staff}}</ref>。

2020年12月18日，[[美國食品藥品監督管理局|美國食品藥品監督管理局]]批准了mRNA-1273的緊急使用授權<ref name="nih-eua">{{cite news |title=Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Moderna COVID-19 Vaccine |url=https://www.nih.gov/news-events/news-releases/statement-nih-barda-fda-emergency-use-authorization-moderna-covid-19-vaccine |access-date=19 December 2020 |agency=US National Institutes of Health |date=18 December 2020}}</ref><ref>{{Cite web|last=Jr|first=Berkeley Lovelace|date=2020-12-19|title=FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution|url=https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html|access-date=2020-12-19|website=CNBC|language=en}}</ref>，並於三日後開始應用於[[美國2019冠狀病毒病疫苗接種計劃|美國2019冠狀病毒病疫苗接種計劃]]。這也是莫德納第一款獲得美國食品藥品監督管理局批准的產品。<ref>{{Cite web|last=Lee|first=Jaimy|title=Moderna nears its first-ever FDA authorization, for its COVID-19 vaccine|url=https://www.marketwatch.com/story/moderna-nears-its-first-ever-fda-authorization-for-its-covid-19-vaccine-11608134670|access-date=2020-12-19|website=MarketWatch|language=en-US}}</ref>

2021年1月8日，英國藥品與保健品管理局批准緊急使用莫德納疫苗<ref>{{cite web |title=Third Covid vaccine approved in the UK |url=https://www.bbc.co.uk/news/health-55586410 |work=BBC News |publisher=BBC |access-date=2021-05-21|date=2021-01-08}}</ref>。然而，該批疫苗一直要到三個月後，才開始於[[英國2019冠狀病毒病疫苗接種計劃|英國2019冠狀病毒病疫苗接種計劃]]應用<ref>{{cite news |title=Patients in Wales to be first in UK to receive Moderna Covid vaccine |url=https://www.theguardian.com/uk-news/2021/apr/07/patients-in-wales-to-receive-moderna-covid-vaccine |work=The Guardian |access-date=2021-05-21|date=2021-04-07}}</ref>。

2021年2月3日，新加坡批准緊急使用莫德納疫苗，成為首個批准該疫苗上市的亞洲國家<ref>{{Cite news|last=Staff|first=Reuters|date=2021-02-03|title=Singapore approves Moderna's COVID-19 vaccine in Asia first|language=en|work=Reuters|url=https://www.reuters.com/article/us-health-coronavirus-singapore-idUSKBN2A30ZM|access-date=2021-06-01}}</ref>。至同年3月21日，此疫苗正式投入[[新加坡2019冠狀病毒病疫苗接種計劃|該國的接種計劃]]。

2021年4月30日，世界卫生组织宣布，将莫德纳疫苗列入紧急使用清单<ref>{{cite news |title=世卫将莫德纳疫苗列入紧急使用清单 |url=https://www.zaobao.com/realtime/world/story20210501-1143515}}</ref>。

2021年5月3日，世界衛生組織主導的疫苗獲得機制（[[COVAX|COVAX]]）宣布已經與莫德納達成一項採購協議，购买5亿剂莫德纳2019冠状病毒病疫苗，将在2021年最后一个季度开始供应，在年底之前将提供3400万剂，到2022年再有4.66亿剂<ref>https://themalaysianreserve.com/2021/05/03/covax-signs-deal-for-500-million-moderna-covid-vaccine-doses/</ref>。

2021年5月5日，[[中華民國|中華民國]][[衛生福利部食品藥物管理署|衛生福利部食品藥物管理署]]發出莫德納疫苗的緊急使用授權<ref name="莫德納疫苗獲緊急授權">{{cite news |title=莫德納疫苗獲緊急授權 自費AZ疫苗供應不間斷 |url=https://www.cna.com.tw/news/firstnews/202105050200.aspx |work=中央通訊社 |date=2021-05-05}}</ref>。截至2021年6月29日，莫德納疫苗已在全球48个国家和地区投入使用<ref>{{Cite web|title=World passes three billion Covid-19 vaccine mark|url=https://www.straitstimes.com/world/europe/world-passes-three-billion-covid-19-vaccine-mark|access-date=2021-06-30|date=2021-06-29|last=hermesauto|work=The Straits Times|language=en}}</ref>。

2022年4月8日，莫德纳表示，在发现一小瓶疫苗被异物污染后，莫德纳将召回其制造商Rovi生产的在歐洲銷售的76.49万剂新冠疫苗。<ref>{{cite news |title=美国莫德纳公司从欧洲召回超76万剂新冠疫苗 来源：央视新闻客户端  2022-04-09 14:38 |url=https://world.huanqiu.com/article/47XHNdK4ElG}}</ref>

==不良反应==
{{seealso|2019冠状病毒病疫苗#心肌炎或心包炎}}

==各地應用情況==
=== 台灣 ===
{{main|臺灣嚴重特殊傳染性肺炎疫苗接種計劃}}
[[衛生福利部|衛生福利部]]於2021年2月10日證實已經與莫德納簽約，莫德納將向台灣供應505萬劑疫苗，預計可於5月或6月運交首批疫苗<ref name="採購莫德納疫苗505萬劑">{{cite news |title=陳時中：採購莫德納疫苗505萬劑 預計第二季分批交付 |url=https://www.rti.org.tw/news/view/id/2091566 |accessdate=2021-04-18 |work=中央廣播電台 |date=2021-02-10}}</ref>。衛生福利部[[食品藥物管理署|食品藥物管理署]]於2021年5月20日證實收到莫德納發出的20瓶疫苗，共200劑的測試標準樣品<ref name="莫德納200劑">{{cite news |title=莫德納要來了？食藥署證實200劑測試標準品抵台 |url=https://www.cna.com.tw/news/firstnews/202105195013.aspx |accessdate=2021-05-29 |work=中央通訊社 |date=2021-05-19}}</ref>。美國政府於2021年6月19日捐贈台灣250萬劑美國生產的莫德納疫苗，並表明美國捐贈疫苗不會附加任何條件<ref name="美國援助疫苗沒有附加條件">{{cite news |title=贈台250萬劑莫德納 美官員：我們的疫苗沒有附加條件 |url=https://news.ltn.com.tw/news/world/breakingnews/3575586 |accessdate=2021-06-20 |work=自由時報 |date=2021-06-19}}</ref>，這250萬劑疫苗於6月20日運抵[[台灣桃園國際機場|台灣桃園國際機場]]<ref name="美國捐贈台灣250萬劑莫德納疫苗">{{cite news |title=美國「真朋友」贈250萬劑莫德納疫苗16:31抵台　陳時中親接機 |url=https://www.upmedia.mg/news_info.php?SerialNo=116414 |accessdate=2021-06-20 |work=上報 |date=2021-06-20}}</ref>。2021年7月22日，衛福部與莫德納宣布雙方達成增購3500萬劑疫苗的協議，將於2022年及2023年分別交付2000萬劑及1500萬劑，除基本型疫苗，也包括加強應對變種病毒的次世代疫苗；另外在今年原有505萬劑疫苗的訂單額外追加多100萬劑，預料追加的疫苗份額可於2021年第四季交付<ref name="莫德納疫苗加購100萬劑">{{cite news |title=莫德納疫苗加購100萬劑 今年第4季供接種 |url=https://www.cna.com.tw/news/firstnews/202107220185.aspx |accessdate=2021-07-25 |work=中央通訊社 |date=2021-07-22}}</ref>。

=== 日本 ===
{{main|日本2019冠狀病毒病疫苗接種計劃}}
[[厚生勞動省|厚生勞動省]]於2020年10月，與莫德納及[[武田藥品工業|武田藥品工業]]達成三方協議，授權武田於2021年上半年引進5,000萬劑莫德納疫苗，並獲授予產品代號「TAK-919」<ref>{{cite news|url=http://med.china.com.cn/content/pid/264802/tid/1026|title=武田：日本批准Moderna新冠mRNA疫苗上市|work=中國醫療|date=2021-05-26|accessdate=2021-07-26}}</ref>。當中，首批疫苗已於2021年5月23日起開始接種<ref>{{cite news |script-title=ja:自衛隊員にモデルナ製ワクチン　国内初、大規模接種会場を運営 |url=https://www.tokyo-np.co.jp/article/106119 |access-date=2021-06-02 |publisher=Tokyo Shimbun |date=2021-05-23}}</ref>。

=== 南韓 ===
{{main|南韓2019冠狀病毒病疫苗接種計劃}}

== 谣言 ==
2021年3月，互联网上开始流传莫德纳疫苗中含有有毒物质的谣言。这一说法起源于3月开始在美国传播，之后在[[抖音|TikTok]]影片和[[Instagram|Instagram]]照片的形式传播开来，并在一周内在[[Facebook|Facebook]]上的分享量已超过1500次。有关文章之后又被社交平台如Exportail、Profession Gendarme、Qactus或AgoraVox以不同的形式在其他国家传播开来。这些文章共同指出，莫德纳疫苗中含有一种物质由90%的[[氯仿|氯仿]]和10%的SM-102组成，对人类健康有害。在有关文章的声明中，也显示了来自美国生物技术公司Cayman Chemical网站的安全数据表的螢幕截图，另一部分的说明书将氯仿列为「危险成分」，同时警告可能会有癌症、不孕症、肾脏、肝脏和中枢神经系统损害的健康风险，一些网站如Qactus也将SM-102认定为是「致命毒药」。在谣言传开后，Cayman Chemical发表声明解释，SM-102是该公司「仅用于实验或临床研究」的产品之一，而具有相同名称的化学品可能有不同的名称，例如由其制造协议和预期用途定义的级别或配方。[[法新社|法新社]]事实核查小组对该訊息进行反驳，并在5月31日公布美国、欧洲或加拿大的监管机构并未将氯仿列为莫德纳疫苗的成分，而[[美国国家职业安全卫生研究所|美国国家职业安全卫生研究所]] (NIOSH)、[[化学物质毒性数据库|化学物质毒性数据库]] (RTECS) 和[[歐洲化學品管理局|歐洲化學品管理局]] (ECHA) 的分类和标签清单都没有列出与SM-102相关的任何危险<ref>{{Cite web|title=Non, le vaccin anti-Covid de Moderna ne contient pas une substance toxique|url=https://factuel.afp.com/http%253A%252F%252Fdoc.afp.com%252F9AV3TT-1|access-date=2021-06-30|date=2021-05-31|work=Factuel|language=fr}}</ref>。

{{main|2019冠状病毒病阴谋论#莫德纳公司制造论}}
2022年3月，流传有莫德纳公司人工制造了[[SARS-CoV-2|SARS-CoV-2]]的传言。

== 參見 ==
*[[辉瑞－BioNTech_2019冠状病毒病疫苗|輝瑞疫苗]]：同期於2020年11月發表第三期臨床試驗報告的[[mRNA疫苗|mRNA疫苗]]

== 參考文獻 ==
{{Reflist|2}}

== 延伸閱讀 ==
* {{cite report | title=Background document on the mRNA-1273 vaccine (Moderna) against COVID-19: background document to the WHO Interim recommendations for use of the mRNA-1273 vaccine (Moderna), 3 February 2021 | vauthors=((World Health Organization)) | year=2021 | publisher=[[世界衛生組織|世界衛生組織]]|id=WHO/2019-nCoV/vaccines/SAGE_recommendation/mRNA-1273/background/2021.1 | hdl=10665/339218}}

== 外部連結 ==
{{scholia}}
{{Commons|Category:MRNA-1273}}
* {{cite web | url=https://www.fda.gov/media/144452/download | format=PDF | title=VRBPAC mRNA-1273 Sponsor Briefing Document | publisher = Moderna | date = 17 December 2020}}
* {{cite web|url=https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf|title=Clinical Study Protocol mRNA-1273-P301|publisher=[[莫德纳|莫德纳]]}}
* [https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf COVID-19 Vaccine Moderna assessment report] [[欧洲药品管理局|欧洲药品管理局]]
* {{cite web | title=How Moderna's Covid-19 Vaccine Works | website=[[纽约时报|纽约时报]] | url=https://www.nytimes.com/interactive/2020/health/moderna-covid-19-vaccine.html }}
* {{cite web | title=Moderna COVID-19 Vaccine | publisher=[[美国疾病控制与预防中心|美国疾控中心]]| url=https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html }}

{{疫苗}}
{{COVID-19}}
{{Portal bar|醫學|病毒|2019冠状病毒病}}

[[Category:美国2019冠状病毒病疫苗|Category:美国2019冠状病毒病疫苗]]
[[Category:2020年面世的產品|Category:2020年面世的產品]]
[[Category:美國發明|Category:美國發明]]
[[Category:RNA疫苗|Category:RNA疫苗]]